Drugs / Bemotrizinol
last change Oct 2022 re-read 2 minutes ago

Bemotrizinol

Developed for
photoallergic dermatitis
Investigated by
NHS Tayside · Spaulding Clinical Research LLC · dsm-firmenich Switzerland AG

Trials 2 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04355286 Nov 2020 dsm-firmenich Switzerland AG Completed No outcome recorded
Phase not applicable1 trial
NCT00530387 Jul 2008 → Jul 2011 photoallergic dermatitis NHS Tayside Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 23 trials
Phase 2 NCT05254912 Comparator Mar → Apr 2022 photoallergic dermatitis dsm-firmenich Switzerland AG Completed No outcome recorded
Phase 2 NCT05254925 Comparator Feb → Mar 2022 phototoxic dermatitis dsm-firmenich Switzerland AG Completed No outcome recorded
Phase 2 NCT05260359 Comparator Feb → Apr 2022 sunburn dsm-firmenich Switzerland AG Completed No outcome recorded
Phase 31 trial
Phase 3 NCT05277376 Comparator Mar → Oct 2022 dsm-firmenich Switzerland AG Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Bemotrizinol ClinicalTrials.gov intervention name — accepted as the source's own label NCT04355286
4

NCT05260359

NCT05254912

NCT05254925

NCT05277376

Known as BEMT “6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (SU E 101413 85)” NCT05254912
1

“6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation” NCT05260359

Known as Benzophenone-3 Benzophenone-3NCT00530387
Known as Neoheliopan AP Neoheliopan APNCT00530387
Known as Octyl salicylate Octyl salicylateNCT00530387
Known as Phenylbenzimidazol sulfonic acid Phenylbenzimidazol sulfonic acidNCT00530387
Known as Tinosorb M Tinosorb MNCT00530387
Known as Tinosorb S Tinosorb SNCT00530387
Route Topical “subjects will receive a topical application of the study drug” NCT04355286